Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: A single-centre retrospective study

Abstract

In view of the acceptable morbidity and mortality rates we propose that CRS combined with HIPEC presents an effective and safe treatment modality for patients with gastric cancer, especially in cases where optimal cytoreduction is achieved before the HIPEC procedure.

Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases

“…There is adequate evidence to judge the safety profile of CRS þ HIPEC for treating GC PM (Table 4) [13,[15][16][17][18][19][20]25,[27][28][29]31,[35][36][37][38][39]. In terms of adverse events, the most frequent adverse events include pleural effusion, ileus, sepsis, wound infection, occlusion, hypoalbuminemia and anastomosis leakage.…”

The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer

“…Intraperitoneally administered chemotherapy has been shown to eradicate the microscopic residual cancer emboli in diseases with peritoneal malignancy. The most characteristic of them are tumours of the gastrointestinal tract with peritoneal carcinomatosis [12], pseudomyxoma peritonei [13], peritoneal mesothelioma [14], peritoneal sarcomatosis [15], or locally advanced ovarian cancer [16]. However, the beneficial effect of HIPEC in peritoneal sarcomatosis has been debated [17].…”

Cytoreductive Surgery and Hyperthermic İntraperitoneal Chemoterapy for Advance Gastric Cancer Associated Peritoneal Carcinomatosis Single Centre Unit for 10 Consecutive Patients

“…Mide serozasının invazyonuyla hastalık yeni bir aşamaya geçip bu aşamada lenf nodu istasyonlarındaki metastazlar daha sıklıkla saptanmaktadır. Serozal tutulunumun bir diğer sonucuda tümör hücrelerinin dökülerek peritoneal karsinomatoza öncülük etmesidir (15). Yapılan araştırmalarda mide kanserinin solid organ metastazları ve buna bağlı gelişen mortaliye oranı %40'larda iken daha erken mortalite ile giden peritoneal karsinomatozisin eşlik ettiği durumda ise bu oran %60'lardadır (16,17).…”